Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology’s Medical Journal “Blood”

Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment… Read More »

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment… Read More »

China NMPA Approves MicuRx’s Contezolid for Treatment of Drug-Resistant Bacterial Infection

China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection

MicuRx Pharmaceutical Co., Ltd. (MicuRx), a leading biopharmaceutical company focused on the discovery, development and commercialization of antibacterial agents against… Read More »

Shanghai Asclepius Meditec and International Department of Central Committee of CPC Collaborate to Provide Emergency Support to Fight COVID-19 in Nepal

Shanghai Asclepius Meditec and International Department of Central Committee of CPC Collaborate to Provide Emergency Support to Fight COVID-19 in Nepal

The President of Asclepius Meditec – the company behind the innovative Hydrogen Oxygen Generator with Nebulizer – Mr. Lin Hsinyung,… Read More »

Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs

Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs

On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech,… Read More »

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that… Read More »

Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting

Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting

Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO)… Read More »

Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody

Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody

Transcenta Holding Limited (“Transcenta”), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced… Read More »

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or… Read More »

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment… Read More »